RAC.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 00:56):

Stats
Today's Volume	268 526
Average Volume	156 358
Market Cap	277.34M
EPS	$0 ( 2024-02-25 )
Next earnings date	( $0 ) 2024-07-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-23.36
ATR14	$0.0110 (0.68%)

Volume Correlation

Long: 0.04 (neutral)

Short: 0.59 (weak)

Signal:(50.719) Neutral

Race Oncology Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Race Oncology Ltd Correlation - Currency/Commodity

-0.32
( neutral )

-0.66
( moderate negative )

0.00
( neutral )

-0.79
( moderate negative )

Race Oncology Ltd Financials

Annual	2023
Revenue:	$3.13M
Gross Profit:	$2.85M (91.03 %)
EPS:	$-0.0617

FY	2023
Revenue:	$3.13M
Gross Profit:	$2.85M (91.03 %)
EPS:	$-0.0617

FY	2022
Revenue:	$707 807
Gross Profit:	$426 611 (60.27 %)
EPS:	$-0.0731

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0794

Financial Reports:

No articles found.

Race Oncology Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Race Oncology Ltd

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.